KRAZATI
Mirati Therapeutics, Inc.
Mark For: KRAZATI™ trademark registration is intended to cover the categories of
| Research |
OneLook
Acronym Finder
|
| Serial Number | 90603915 |
| Mark Literal Elements | KRAZATI |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | TRADEMARK. SERVICE MARK |
| Register | PRINCIPAL |
| Current Location | INTENT TO USE SECTION 2022-04-19 |
| Basis | 1(b) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | No |
| Intent To Use | Yes |
| Filed ITU | Yes |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Eric R. Moran |
| Attorney Docket Number | 21-0416-US |
Timeline
| 2021-03-25 | Application Filed |
| 2021-03-29 | Location: NEW APPLICATION PROCESSING |
| 2021-03-29 | Status: Live/Pending |
| 2021-03-30 | Transaction Date |
| 2022-02-22 | Published |
| 2022-04-19 | Location: INTENT TO USE SECTION |
| 2022-10-17 | Status: A first request for extension of time to file a Statement of Use has been granted. |
Trademark Parties (Applicants & Owners)
| Party: |  Mirati Therapeutics, Inc. |
| Address | 3545 Cray Court San Diego, CALIFORNIA UNITED STATES 92121 |
| Legal Entity Type | Corporation |
| Legal Entity State | DELAWARE |
Documents
 Application | 2021-03-25 | |
| Drawing | 2021-03-25 | |
| Change Address or Representation Form | 2021-06-30 | |
| XSearch Search Summary | 2021-11-06 | |
| XSearch Search Summary | APPLICATION/XML | 2021-11-06 |
| Offc Action Outgoing | 2021-11-08 | |
| Amendment and Mail Process Complete | 2021-11-10 | |
| Response to Office Action | 2021-12-20 | |
| Amendment and Mail Process Complete | 2021-12-21 | |
| Examiners Amendment | 2022-01-15 | |
| Amendment and Mail Process Complete | 2022-01-18 | |
| TRAM Snapshot of App at Pub for Oppostn | 2022-01-19 | |
| Notice of Publication | 2022-02-02 | |
| Notification Of Notice of Publication | 2022-02-02 | |
| OG Publication Confirmation | 2022-02-22 | |
| Notice of Allowance | 2022-04-19 | |
| Extension of Time to File SOU | 2022-10-17 | |
| ITU Extension Approval | 2022-10-19 | |
| ITU Unit Action | 2022-10-19 |
Attorney of Record
Good, Services, and Codes
IC 005. US 005 006 018 044 046 051 052. G & S: pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors
IC 042. US 100 101. G & S: research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0051 | pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors |
| GS0051 | pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2022-10-19 | |
| TEAS EXTENSION RECEIVED | 2022-10-17 | |
| SOU EXTENSION 1 GRANTED | 2022-10-17 | 98765 |
| SOU EXTENSION 1 FILED | 2022-10-17 | 98765 |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2022-04-19 | |
| PUBLISHED FOR OPPOSITION | 2022-02-22 | |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2022-02-22 | |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2022-02-02 | |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2022-01-18 | |
| NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2022-01-15 | 6328 |
| EXAMINERS AMENDMENT E-MAILED | 2022-01-15 | 6328 |
| EXAMINERS AMENDMENT -WRITTEN | 2022-01-15 | 86336 |
| EXAMINER'S AMENDMENT ENTERED | 2022-01-15 | 88888 |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2021-12-20 | 88889 |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2021-12-20 | |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2021-12-20 | 88889 |
| ASSIGNED TO LIE | 2021-11-09 | 96335 |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2021-11-08 | 6325 |
| NON-FINAL ACTION WRITTEN | 2021-11-08 | 86336 |
| NON-FINAL ACTION E-MAILED | 2021-11-08 | 6325 |
| ASSIGNED TO EXAMINER | 2021-11-01 | 86336 |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2021-07-01 | |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2021-06-30 | |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2021-06-30 | |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2021-06-30 | 88888 |
| NEW APPLICATION ENTERED IN TRAM | 2021-03-29 |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 